Loracarbef is an antibiotic. Its use was discontinued in 2006. It is a carbacephem, but it is sometimes grouped together with the second-generation cephalosporin antibiotics. It was marketed under the trade name Lorabid. Loracarbef is a synthetic "carba" analogue of cefaclor, and is more stable chemically. Diarrhea is the most common adverse effect with Loracarbef. Side effects are more frequently seen with children under the age of twelve. It received FDA approval in 1991.